Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in… | ScholarDeck

Paper

Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.

New research · Medical Genetics & Genomics

Blood cancer discovery · 3w

Cohort studyBlood cancer discovery· Aug 2026

Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.

Ruwan Gunaratne, Crystal M Zhou, Sanjeeth Rajaram … Tian Yi Zhang

Read paper

Molecular Genetic PathologyCohort studyPrognosisQ1IF 7.3

Plasma ctDNA MRD detection strongly predicts relapse-free survival in acute myeloid leukemia

Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.

Ruwan Gunaratne … Tian Yi Zhang

Blood cancer discovery · Aug 2026

Background

Relapsed and/or refractory disease remains the leading cause of death in AML, highlighting the need for broadly applicable, high-sensitivity approaches to MRD detection.

HR 17.8

Results

HR 17.8

17.8-fold higher relapse risk when ctDNA MRD is detected

n = 56 patients

More results

In 56 patients with longitudinal plasma and matched peripheral blood and bone marrow samples, AML-CAPP-Seq enabled universal MRD assessment and resolution of clonal dynamics using a median of 30.5 variants per patient.

Among 29 allogeneic transplant recipients, peri-transplant ctDNA-MRD dynamics markedly improved relapse risk stratification (HR 36.0, p=0.0009).

“

Conclusion

Together, these results establish personalized ctDNA profiling as a minimally invasive, highly sensitive, and generalizable platform for enhanced clinical MRD detection and clonal surveillance in AML.

Read paper